Esophageal and Esophagogastric Junction Cancers, Version 1.2015
Top Cited Papers
- 17 February 2015
- journal article
- research article
- Published by Harborside Press, LLC in Journal of the National Comprehensive Cancer Network
- Vol. 13 (2), 194-227
- https://doi.org/10.6004/jnccn.2015.0028
Abstract
Esophageal cancer is the sixth most common cause of cancer deaths worldwide. Adenocarcinoma is more common in North America and Western European countries, originating mostly in the lower third of the esophagus, which often involves the esophagogastric junction (EGJ). Recent randomized trials have shown that the addition of preoperative chemoradiation or perioperative chemotherapy to surgery significantly improves survival in patients with resectable cancer. Targeted therapies with trastuzumab and ramucirumab have produced encouraging results in the treatment of advanced or metastatic EGJ adenocarcinomas. Multidisciplinary team management is essential for patients with esophageal and EGJ cancers. This portion of the NCCN Guidelines for Esophageal and EGJ Cancers discusses management of locally advanced adenocarcinoma of the esophagus and EGJ. Esophageal cancer is the sixth most common cause of cancer deaths worldwide. Adenocarcinoma is more common in North America and Western European countries, originating mostly in the lower third of the esophagus, which often involves the esophagogastric junction (EGJ). Recent randomized trials have shown that the addition of preoperative chemoradiation or perioperative chemotherapy to surgery significantly improves survival in patients with resectable cancer. Targeted therapies with trastuzumab and ramucirumab have produced encouraging results in the treatment of advanced or metastatic EGJ adenocarcinomas. Multidisciplinary team management is essential for patients with esophageal and EGJ cancers. This portion of the NCCN Guidelines for Esophageal and EGJ Cancers discusses management of locally advanced adenocarcinoma of the esophagus and EGJ.Keywords
This publication has 80 references indexed in Scilit:
- Chemotherapy followed by surgery versus surgery alone in patients with resectable oesophageal squamous cell carcinoma: Long-term results of a randomized controlled trialBMC Cancer, 2011
- Is concurrent radiation therapy required in patients receiving preoperative chemotherapy for adenocarcinoma of the oesophagus? A randomised phase II trialEuropean Journal Of Cancer, 2011
- HER2 diagnostics in gastric cancer—guideline validation and development of standardized immunohistochemical testingVirchows Archiv, 2010
- Phase II Randomized Study of Two Regimens of Sequentially Administered Mitomycin C and Irinotecan in Patients with Unresectable Esophageal and Gastroesophageal AdenocarcinomaJournal of Thoracic Oncology, 2010
- Randomised, non-comparative phase II study of weekly docetaxel with cisplatin and 5-fluorouracil or with capecitabine in oesophagogastric cancer: the AGITG ATTAX trialBritish Journal of Cancer, 2010
- Phase II trial of docetaxel–irinotecan combination in advanced esophageal cancerAnnals of Oncology, 2009
- Association of ERBB2 gene status with histopathological parameters and disease-specific survival in gastric carcinoma patientsBritish Journal of Cancer, 2009
- Incidence of Adenocarcinoma of the Esophagus Among White Americans by Sex, Stage, and AgeJNCI Journal of the National Cancer Institute, 2008
- The role of staging laparoscopy in oesophagogastric cancersEuropean Journal of Surgical Oncology, 2007
- Phase III Study of Docetaxel and Cisplatin Plus Fluorouracil Compared With Cisplatin and Fluorouracil As First-Line Therapy for Advanced Gastric Cancer: A Report of the V325 Study GroupJournal of Clinical Oncology, 2006